Inactive Instrument

Highlights CymaBay Therapeutics, Inc.

Equities

CBAY

US23257D1037

Highlights

Unlock all the news: Be the first to know and act before the market!

Gilead Sciences Completes $4.3 Billion Cymabay Acquisition	Mar. 22	MT
Gilead Sciences, Inc. completed the acquisition of CymaBay Therapeutics, Inc..	Mar. 21	CI
Gilead Sciences Says Antitrust Waiting Period for CymaBay Therapeutics Deal Expires	Mar. 11	MT
CymaBay Says European Medicines Agency to Review Marketing Authorization Application for Seladelpar	Mar. 04	MT
CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis	Mar. 04	CI
CymaBay Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
CymaBay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
North American Morning Briefing : Stocks Seen -2-	Feb. 13	DJ
News Highlights: Top Company News of the Day - Monday at 7 PM ET	Feb. 12	DJ
Health Care Up on Deal Activity -- Health Care Roundup	Feb. 12	DJ
News Highlights : Top Company News of the Day - Monday at 5 PM ET	Feb. 12	DJ
News Highlights : Top Company News of the Day - Monday at 3 PM ET	Feb. 12	DJ
News Highlights : Top Company News of the Day - Monday at 1 PM ET	Feb. 12	DJ
News Highlights : Top Company News of the Day - Monday at 11 AM ET	Feb. 12	DJ
Gilead Eyes Expanded Liver Treatment Portfolio With $4.3 Billion Buyout of CymaBay Therapeutics	Feb. 12	MT
Trending : Gilead Sciences to buy CymaBay for $4.3 Billion	Feb. 12	DJ
CymaBay Therapeutics Receives US FDA Acceptance, Priority Review for Seladelpar to Treat Primary Biliary Cholangitis	Feb. 12	MT
CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal	Feb. 12	DJ
News Highlights : Top Company News of the Day - Monday at 9 AM ET	Feb. 12	DJ
Gilead Sciences Signs Deal to Acquire CymaBay Therapeutics for $4.3 Billion	Feb. 12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CymaBay Therapeutics, Inc.

Equities

CBAY

US23257D1037

Highlights

Filters